Purpose of this Study
Duke will give patients three special inhalers called Airsupra to use when they need help breathing. Normally, patients use an inhaler called albuterol, but in this study, some patients will use Airsupra instead. After leaving the emergency room, the study team will check on patients at about 3, 6, and 12 weeks to see how they are doing and if they have any problems with their inhaler. Most check-ins will be by phone, but email may be used if the patient prefers or to make sure all information is collected.
Who Can Participate?
Eligibility
People can join the study if they have a sudden asthma attack, are between 18 and 54 years old, and speak English or Spanish. They must be sent home from the emergency room with a short treatment of steroid medicine. For the group using Airsupra, they must agree to use this inhaler, which has two medicines in one, and show they know how to use the inhaler correctly.
Age Range
18-60
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The study wants to find out if using Airsupra in the emergency room helps people control their asthma better after 3 months compared to usual care. It also wants to see if Airsupra can lower the chances of having another asthma attack within 3 weeks after leaving the emergency room.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
45th Multicenter Airway Research Collaboration (MARC-45): A phase 4, multicenter, cluster randomized, open-label, intervention versus usual care, controlled study on the effect of emergency department initiation of Airsupra on asthma outcomes
Principal Investigator
Lauren
Siewny
Protocol Number
PRO00118956
NCT ID
NCT07166939
Phase
IV
Enrollment Status
Pending Open to Enrollment